Catalysts 1 drug sales updates 2 IBS-C approval Potential Catalysts 1 partnership/merger/buyout 2 (unlikely) hostile takeover 3 (unlikely) activist investor intervention 4 further dilution FWIW: from drugs.com Linzess User Ratings 10 41% (94) 9 16% (36) 8 8% (18) 7 5% (11) 6 6% (13) 5 4% (7) 4 4% (8) 3 5% (10) 2 4% (7) 1 13% (29) Trulance User Ratings 10 63% (10) 9 19% (3) 8 0% (0) 7 0% (0) 6 0% (0) 5 7% (1) 4 0% (0) 3 7% (1) 2 0% (0) 1 7% (1) It's really early, but there are not as many tolerability complaints as I recall with Linzess out of the gate.